GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline (GSK) is currently conducting a Phase 3b clinical study titled An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study. The study aims to determine the optimal revaccination timing for the RSVPreF3 OA vaccine, assess long-term immune persistence and safety over five RSV seasons, and provide the vaccine to participants who previously received a placebo.
The intervention being tested is the RSVPreF3 OA vaccine, a biological treatment intended to prevent respiratory syncytial virus (RSV) infections in older adults. The study involves administering the vaccine at various time points to evaluate its effectiveness and safety.
This interventional study employs a randomized, parallel assignment model without masking, focusing on prevention. Participants are divided into groups receiving the vaccine at different intervals or not receiving additional doses, with some receiving the vaccine for the first time.
The study began on August 1, 2024, with the latest update submitted on August 6, 2025. These dates are crucial as they mark the study’s progress and the timeline for potential results that could impact vaccine availability.
For investors, this study’s progress could influence GSK’s stock performance, as successful outcomes may enhance the company’s market position in the competitive vaccine industry. The study’s results could also affect investor sentiment, particularly in the context of increasing demand for effective RSV prevention in older populations.
The study is ongoing, with further details available on the ClinicalTrials portal.